RxSight (RXST) Long-Term Deferred Tax (2022)
RxSight posted quarterly Long-Term Deferred Tax of $91.6 million for Q4 2022.
RxSight (RXST) has 1 years of Long-Term Deferred Tax data on file, last reported at $91.6 million in Q4 2022.
- For the quarter ending Q4 2022, Long-Term Deferred Tax changed N/A year-over-year to $91.6 million; the trailing twelve-month figure through Dec 2022 stood at $91.6 million (changed N/A YoY), and the FY2022 full-year result was $91.6 million, changed N/A from the prior year.
- Long-Term Deferred Tax for Q4 2022 stood at $91.6 million.
- Across five years, Long-Term Deferred Tax topped out at $91.6 million in Q4 2022 and bottomed at $91.6 million in Q4 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | RxSight | 215.82 Mn | -2.06 Mn | 23.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 91.63 Mn |